Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PR3152 (cleefy) > PR3152 IC19 > Flashcards

PR3152 IC19 Flashcards

1
Q

what is the physiology of the prostate

A

1) epithelial cells (glandular): growth stimulated by androgens
2) stroma cells (smooth): innervated by alpha1 adrenergic receptors

testosterone is converted into DHT by 5alpha-reductase.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the pathophysiology of BPH?

A

1) static component
- hormone factors (testosterone -> DHT) = enlargement of prostate tissue

2) dynamic component
- increase smooth muscle tissue and agonism of alpha 1 receptors = narrowing of urethra

= urethral obstruction and other s/sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is the pathophysiology of BPH in the long term, relating to bladder

A

the detrusor muscle must contract hard to force the urine out of the narrow urethra = hypertrophy = at the highest level of hypertrophy, the detrusor muscle compensates = bladder becomes irritative and highly sensitive = contract abnormally w/ smallest amounts of urine = increase urinary frequency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is LUTS

A

lower urinary tract symptoms (LUTS)
- nocturia, frequency, urgency, intermittent stream, straining, weak stream, incomplete emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

progression of BPH in males? relate to age

A

more patients are asymptomatic until 65yo, where 1/3 will start to develop symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are the two types of s/sx for BPH?

A

1) obstructive/voiding (typically early on)
- sensation of incomplete emptying
- dribbling
- weak stream
- intermittent stream
- hesitancy
- straining

2) irritative/storage (after several years, when detrusor starts to decompensated)
- frequency
- urgency
- nocturia
- dysuria (pain during urination)
- urinary incontinence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

assessment methods for BPH

A

1) maximum urinary flow rate (Qmax)

2) Prostate specific antigen (PSA)
- not specific to BPH, but can monitor BPH progression. PSA ideally <1.5, may indicate risk of prostate cancer.

3) Post void residual (PVR)
- <100 = normal
- >200 = urinary retention

4) digital rectal exam (DRE)

5) ultrasonography

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

IPSS

A

7 sections, total of 5 per section, up to 35 max points

also includes QOL, up to 6 points.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MOH LUTS

A

4 grades

I) QOL <3, PVR < 100, treatment not needed

II) QOL ≥3 PVR <100, phx

III) QOLNIL PVR >100, Qmax<10ml/s surgical option

IV) QOLNIL, (urine retention, recurrent UTI, bladder calculi, persistent macroscopic hematuria)
surgery TURP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

medication risk factors for BPH

A

need to remove risk factor

opioid analgesics = increases urinary retention

anticholinergics (tricyclic antidepressants eg -triptylines, antihistamines) = block acetylcholine which send signals for bladder contraction = reduces bladder muscle contractility

testosterone = increase prostate size

diruetics = increase urinary frequency

alpha 1 agonists (decongestants) = contract prostate smooth muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

when do you not need to initiate treatment for BPH

A

if patient has IPSS < 8 or

mod-severe (IPSSS≥8) with QOL <3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

non phx measures for bPH

A

1) limit fluid intake at night
2) avoid caffeine or alcohol intake
3) counsel patient to have complete and frequent urination
4) avoid meds that worsen symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what to consider when initiating treatment for BPH

A

comorbidities
IPSS (luts severity)
prostate size
PSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

describe the alpha adrenergic antagonists (types, onset, and any specific instructions) in BPH

A

alpha1 adrenergic antagonists

1) non-selective: affect the peripheral vascular and urinary a1 receptors
- DTP: doxazosin, terazosin, prazosin (P not used)
- risk of hypotension and syncope = require dose titration slowly.

2) selective: selectively affect the urinary a1 receptors
- SAT: silodocin, alfuzocin, tamsulosin
- do not require dose titration.

onset is days to weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

indication of alpha adrenergic antagonists in BPH

A

for patients with moderate to severe LUTS with small prostate <40g

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

downsides to alpha adrenergic antagonists in BPH

A

no effect on PSA
s/sx recur if discontinue
does not reduce prostate size or reduce progression of disease (only helps with symptomatic management)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

benefits to alpha adrenergic antagonists in BPH

including onset time

A

fast onset of days to weeks

potentially beneficial in patients with concomitant HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

side effect profile for alpha adrenergic antagonists in BPH

A

general: muscle weakness, fatigue, headache, ejaculatory abnormalities

uroselective: ejaculatory abnormalities
S>T>A

non-selective: dizziness, first dose syncope, hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what medical condition to check when initiating alpha adrenergic antagonists and what to do w med admin in BPH

A

check for IFIS
- intraoperative floppy iris syndorms

caused by alpha adrenal blocking at the iris dilator muscle, complicates cataract surgery - likely cause = tamsulosin

to stop alpha blockers at least 14 days before surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

administration instructions for non-selective alpha adrenergic antagonists in BPH

A

to take at night to reduce risk of orthostatic hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what (and when) is the indication for 5ARIs in BPH

A

patients with moderate to severe LUTS and prostate size >40g

patients who cannot tolerate SE of alpha blockers OR do not want surgery

consider initiating if PSA >1.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what are the 5ARI drugs in BPH

A

finasteride and dutasteride

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

benefits of 5ARI in BPH?

A

reduces PSA levels (consider initiating if PSA >1.5)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

downsides of 5ARI in BPH?

A

slow onset 6-12months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

side effect profile of 5ARI?

A

decreased libido
increased risk ejaculation abnormalities vs alpha blockers
erectile dysfunction
gynaecomastia
lesser HTN risk

5ARI increases the amount of circulating testosterone that (not converted to androgen) is now converted into estrogen, leading to development of female features = gynaecomastia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

contraindications for 5ARI?

special population

A

women and children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

additional labs to take before initiating 5ARI in BPH?

A

obtain PSA before starting as it is difficult to interpret after initiating

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

indications for PDE5i in BPH?

A

adjunctive therapy for BPH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

administration and onset of PDE5i for BPH?
include the drug approved

include the drug used

A

tadalafil
adminster irregardless of sexual activity
onset days to weeks

30
Q

when should monotherapy for PDE5i for BPH be initiated?

A

low BMI, young age, higher baseline symptoms

31
Q

who are more likely to benefit from combination therapy?

A

moderate luts (IPSS 8-19), QOL (5-6), prostate >25g

32
Q

a1 antagonist + 5ari combination for BPH?

A

alpha blocker onset in weeks to help manage symptoms, while 5ari onset in months to control the size of prostate

symptomatic patients with enlarged prostate

after 6 months can consider discontinuing alpha blocker.

33
Q

PDE5i + 5ari combination for BPH?

A

help to mitigate 5ari side effects causing sexual disturbance/concomitant ED

however, risk of cardiac problems (commonly associated with ED patients)

avoid nitrate use eg GTN

34
Q

a1 antagonist + PDE5i combination for BPH?

A

not recommended due to significant risk of LIFE THREATENING hypotension. if initiated:

start with optimising and stabilising alpha blocker dose

before adding pde5i at the lowest dose

35
Q

when should antimuscarinics be added for BPH? (and initiated when)

A

for irritative/storage symptoms

initiate if patient PVR <250 (150 in some guidelines)

36
Q

MOA of antimuscarinics for BPH

A

inhibits smooth muscle contraction of bladder (detrusor) by blocking muscarinic receptor = decrease involuntary contraction

37
Q

name the antimuscarinic BPH agents?

A

SOFTT -(blaDAR)

solifenacin
oxybutinin
fesoterodine
tolerodine
trospium
darifenacin

38
Q

what is the definition of erectile dysfunction (ED)?

A

> 6 months unable to have or maintain erection to have satisfactory sexual intercourse

39
Q

what is the physiology of erection

A

activation of parasympathetic nervous system:
1) ach increase = increases in cGMP
2) ach and prostaglandin E increase = increase in cAMP
= combined to increase smooth muscle relaxation and vasodilation
= corpus carvenosa fills with blood (inflow increased)
= presses against the tunica albuginea (outflow decreased)
= erection

testosterone plays contributory role but should be assessed with patient symptoms. patient may have low testosterone but no ED

40
Q

what are the normal testosterone levels

A

300- 1000 ng/dL
10.4 - 38.2 nmol/L

41
Q

what is the physiology of detumescence?

A

parasympathetic deactivation
- PDE5 degradation of cGMP to 5GMP = reduced smooth muscle relaxation and increased vasoconstriction

sympathetic activation
- a2 adrenergic receptors = induce smooth muscle contraction = reduced blood flow

42
Q

what is the etiology of ED

A

1) organic
2) psychogenic
3) mixed
4) others: social habits (smoking, drinking, illicit drug use), obesity

43
Q

what are the factors in organic ED

A

1) vascular
2) hormonal
3) neurological
4) medication-related causes

44
Q

what are the vascular causes in organic ED

A

atherosclerosis
DM
HTN
PVD

45
Q

what are the hormonal causes in organic ED

A

related to lack of testosterone
- hypogonadism
- hyperprolactinemia (increased prolactin = decreased testosterone and sperm production)

46
Q

what are the neurological causes in organic ED

A

primary: CNS disorders

secondary: neuropathy, DM, urethral surgery

47
Q

what are the medication-related causes to organic ED (include moa)

A

BADSBC
1) BP medications: methydopa, betablockers (except ), thiazide diuretics = decreased blood flow

2) Anticholinergic agents: 1st gen antihistamines, tricyclic antidepressants (e.g. -triptyline) = decreased Ach activity

3) Dopamine Antagonists: metoclopramide = dopamine related to sexual arousal/stimulation

4) SSRIs = increase serotonine in brain/decrease testosterone

5) BPH meds: 5ARIs = decreases testosterone

6) CNS depressants: benzodiazepines, anticonvulsants =suppress perception of psychic stimulus

48
Q

what are the causes of psychogenic ED?

A

Malaise
Loss of attraction
Stress
Performance anxiety
Mental Disorders
Sedation

49
Q

EDdiagnosis/ evaluation criteria?

A

1) signs and symptoms
2) SHIM (sexual health inventory for men)
<11 = moderate to severe ED (mild is 17-21; goes up to 25 max)
3) patient medical history for underlying causes
- social history, med/medication history, surgical history, lab results (lipid, glucose, testosterone)

50
Q

why should CVS evaluation be initatied in ED patients?

A

1) possible early symptom of unidentified CVS problems
2) sexual intercourse = increase in sympathetic activation = BP and HR = risk of myocardial infarction

51
Q

CV risk factors for ED and what to do?

A

if unknown or not low risk: test exercise capacity using exercise stress test.

if unstable/severe symptomatic CVD: defer sexual activity until the condition stabilises

cardiac rehab and regular exercise needed to reduce the risk of CV complications with sexual activity

52
Q

non phx measures for ED?

A

1) address modifiable RF:
control weight, BP, lipids, glucose
exercise
stop smoking
decrease alcohol

2)psychotherapy
3) vacuum erection device (ved)
4) surgery eg. penile implant

53
Q

what are the PDE5i agents for ED? include special instructions

A

SVTA
Sildenafil
- take with food. hepatic and renal dose adjustment

Vardenafil
- take with food. hepatic adjustment

Tadalafil
- long duration of action 36h
- can be taken daily (OD)
- take irregardless food. hepatic and renal dose adjustment

Avanafil
- take irregardless food.

54
Q

when to lower dose of PDE5i for ED?

A

if
- age >65
- taking alpha blocker
- renal failure
- cyp3a4 inhibitors e.g. macrolide, cimetidine, conazole antifungal, protease inhibitors

55
Q

what are the SE for PDE5i

A

muscle and back pain (pde11 in MSK)

headache, rhinitis, flushing, dizziness, hypotension (relax arteries throughout body = increase flow)

priapism (for more than 4h = goA&E)

sudden hearing loss (rare) (due to increased blood flow to the ear)

ocular problems (PDE6):
- sensitivity to light
- colour discrimination problem (blue-green tinting of vision)

56
Q

what are the food + drug interactions for PDE5i

A

X nitrates

X antihypertensives
X cyp3a4 inhibitors
X alcohol = hypotension

57
Q

what are the monitoring parameters for PDE5i (efficacy and safety)

E.G. if failure reported also

A

efficacy
-If failure reported;
* Administration with food?
* Timingandfrequencyofdosing
* Lack of adequate sexual stimulation
* Titration to maximum dose
* If all modifiable factors are addressed, may be treated with a different PDE5 inhibitor or proceed with other more invasive therapy

safety
* BP
* Side effects
* Drug interactions
* Changes in cardiac health status

58
Q

when to initiate testosterone for ED?

A

symptomatic gonadism with
1) reduced serum testosterone (should fall below the normal range of 300-1100ng/dl OR 10.4-38.2nmol/L)
2) decreased libido

59
Q

SE of testosterone for ED?

A

circulatory system related
- polycythemia
- increase BP
- dyslipidemia

mood
- irritability
- aggression

other organs
- hepatotoxicity
- prostatic hyperplasia

others
- undesirable hair growth

60
Q

dosage forms of testosterone for ED?

A

Dosage forms: IM injection, buccal, patches, topical gel, body spray, nasal spray & PO

61
Q

monitoring freq of testosterone for ED?

A

within 1-3 months monitoring then every 3-6 months.
if no effect after 3 months = discontinue

62
Q

MOA of alprostadil

A

prostaglindin E analog
= stimulate production of cAMP = increased vasodilation and smooth muscle relaxation = erection

no need for sexual stimulation for effect

63
Q

onset, DOA, DDI, SE of alprostadil

A

5-10min onset
for intraurethral = 30-60min duration of action
DDI: PDE5i
SE: pain, warmth or burning sensation in the urethra, voiding difficulties, bleeding or spotting, priapism, partners may experience vaginal burning or itching

no need sexual stimulation

64
Q

intraurethral alprostadil pellets vs intracavernosal alprostadil

A

intracarvenosal has better efficacy
BUT
higher risk of priapism, bleeding, hematoma, fibroids
+
disadvantages: fear of needles, invasiveness, lack of spontaneity, complicated administration technique

65
Q

titration for alprostadil intracavernosal

A

titrate in healthcare setting to erection that is maintain for ≤1 hr

self administer no more than 3 times per week

66
Q

what is yohimbine

A

alpha 2 antagonist
controversial

67
Q

side effect specific to tadalafil (more likely)

A

muscle pain due to afinity to pde11

68
Q

side effect specific to vardenafil

A

QTC prolongation

69
Q

PDE5i more likely to cause ocular problems( what + explain reasoning)

A

NAOINS: nonartertic anterior ischemic optic neuropathy
- sildenafil and vardenafil
- due to PDE5i causing hypoperfusion to the optic nerve resulting in ischemia

70
Q

risk factors for NAION + counselling (PDE5i induced)

non artheritic ischemic optic neuropathy

A

DM, smoking, htn, cvd, dyslipidemia, >50yo

if sudden vision loss/decreased vision = stop and go doctor

71
Q

counselling points of PDE5i with nitrates?

A

12h: avanafil
24h: sildenafil and vardenafil
48h: tadalafil

PR3152 (cleefy) (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions